Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab in Systemic AL Amyloidosis
NCT06699394Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of teclistamab in systemic light chain amyloidosis, sponsored by Peking University People's Hospital. Primary endpoint: Complete Hematological Response at 6 months. Started Mar 2025; status: recruiting.
02
Drugs
teclistamab
03
Conditions
systemic light chain amyloidosis
Beyond the preview
Go deeper on NCT06699394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06699394.